
    
      This will be a multi-center, open-label, single-dose, study to assess the pharmacokinetics of
      Aptensio XR® (methylphenidate hydrochloride extended-release) capsules in male and female
      children 4 to under 6 years of age with ADHD in fed condition.

      Screening Procedures: After obtaining written informed consent from parents, subjects will
      undergo a complete medical and medication history, demographic data (including sex, age,
      race, ethnicity, body weight (kg), height (cm), Body Mass Index (BMI) (kg/m2), physical
      examination, vital signs evaluation (sitting blood pressure, pulse rate, respiration rate,
      temperature and pulse oximetry), resting 12-lead electrocardiogram (ECG), clinical laboratory
      tests and concomitant medication within 28 days prior to receiving study drug. On Day 1:
      subjects will receive a single oral dose of Aptensio XR®.
    
  